• Current

Proretina Therapeutics
Development of drugs for the treatment of retinal dystrophies and degenerations

About Us

About us | Proretina TherapeuticsProretina Therapeutics is a spin-off of the Centre for Biological Research (CIB). We develop drugs for the treatment of retinal dystrophies and degenerations.

Pipeline

Pipeline | Proretina Therapeutics Our core lines of development are based on two projects, namely PRO-001, whose active ingredient is a neuroprotective agent for the treatment of retinitis pigmentosa, and PRO-015.

Job Opportunities

Job Opportunities | Proretina Therapeutics At Proretina Therapeutics we are constantly seeking for new talent. Access our job listings to check out the latest vacancies and / or to send us your CV.

Featured news
Proretina raises 1.16 million in new capital
Friday, 9 December 2011

Proretina raises 1.16 million in new capital

Sociedad de Desarrollo de Navarra (SODENA), Inveready S.C.R., Navarra Banca... more

Meeting with patients by Retinitis Pigmentosa 2011
Thursday, 26 May 2011

Meeting with patients by Retinitis Pigmentosa 2011

On 26 May 2011, ProRetina Therapeutics, S. L. held the "Meeting with patients... more